Artwork

Dementia Researcher에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dementia Researcher 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

A Closer Look At Lecanemab Donanemab And Amyloid

54:21
 
공유
 

Manage episode 383216087 series 2114488
Dementia Researcher에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dementia Researcher 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.
  continue reading

266 에피소드

Artwork
icon공유
 
Manage episode 383216087 series 2114488
Dementia Researcher에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dementia Researcher 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.
  continue reading

266 에피소드

Alle episoder

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드